Delivery Order SPE2DB24D2205-SPE2DB25FEGYA
Award Date 8/28/25
Potential Completion Date 8/29/25
Potential Value $37K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $22,237.80 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 21, 2025. This firm fixed-price, non-competitive set-aside contract is scheduled for completion by August 22, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for moderate-to-severe atopic dermatitis,...
- On August 15, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $97,415.40 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $43,275.69. This firm fixed-price, non-set-aside contract is scheduled for completion by August 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on August 18, 2025, with an ultimate completion date of August 19, 2025. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The contract utilizes firm fixed pricing with no set-aside designation, indicating open competition. AmerisourceBergen...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency awarded a delivery order valued at $6,447.84 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitive, firm fixed-price delivery order is scheduled for completion by August 4, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order valued at $37,531.67 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat atopic dermatitis, eosinophilic esophagitis, and asthma,...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...